Abstract Background/Purpose: To obtain current epidemiological data for better vaccination policies, this study aimed to assess the incidence and risk factors of herpes zoster in human immunodeficiency virus (HIV)-positive patients initiating combination antiretroviral therapy (cART) in Taiwan. Methods: Between June, 2012 and May, 2015, we prospectively identified zoster cases in HIVpositive patients initiating cART. Clinical information was collected on demographics, prior zoster, plasma HIV-1 RNA load (PVL), and CD4 count at baseline and during follow up. A caseecontrol study by 1:2 matched pairs was used to identify the risk factors for zoster development. Results: During the 3-year study period, 826 patients with a mean age of 32.9 years were included, and 7.7% had prior zoster. The mean baseline CD4 count and PVL were 286 cells/ mL and 4.90 log 10 copies/mL, respectively. Fifty-four (6.5%) patients developed zoster after initiation of cART, with 43 episodes (79.6%) occurring within 1 year of cART initiation, which corresponded to an overall incidence rate of 3.61/100 person-years. The multivariate analysis revealed that prior zoster (adjusted odds ratio Z 3.143; 95% confidence interval, 1.385e7.133) and baseline CD4 count < 200 cells/mL (adjusted odds ratio Z 2.034; 95% confidence interval, 1.020e4.057) were independent risk factors for zoster in HIV-positive patients initiating cART. In caseecontrol study, prior zoster and baseline PVL > 5 log 10 copies/mL were risk factors for zoster development after cART initiation in multivariate analysis. Conclusions: Herpes zoster occurred in 6.5% of HIV-positive Taiwanese patients after initiation of cART, which was associated with prior zoster and baseline CD4 count < 200 cells/mL or baseline PVL > 5 log 10 copies/mL.
Introduction
Herpes zoster, also called shingles, is most often seen in the elderly population. It also commonly occurs in human immunodeficiency virus (HIV)-positive patients. 1e3 Prior to the introduction of combination antiretroviral therapy (cART), the incidence of herpes zoster was estimated to be 10e30 times greater in HIV-positive patients than in HIVnegative individuals. 1, 4, 5 Several studies reported incidence rates of 2.5e3.2 cases/100 person-years in different HIV-positive cohorts. 3, 6 A low CD4 count was the risk factor for developement of herpes zoster. 4, 7 After the introduction of cART, the incidence of herpes zoster declined significantly 7e10 ; 1.2 cases/100 person-years was observed in Germany and 0.9 cases/100 person-years in the United States in the cART era. 9, 10 This decrease was mainly attributable to the restoration of immunity with cART. However, the incidence remains higher in HIV-positive patients in the cART era than that in the general population of resource-rich countries, which ranges from 0.2/100 personyears to 0.5/100 person-years. 11, 12 Complication rates are also higher in HIV-positive patients than in the age-matched general population (27e28% vs. 10e13%). 6, 10, 13, 14 Therefore, use of herpes zoster vaccine may be considered in HIV-positive patients to prevent herpes zoster and its related complications.
Live attenuated herpes zoster vaccine (LAHZV) was recommended to HIV-positive adults with a CD4 count >200 cells/mL. 15, 16 Recently, an adjuvanted herpes zoster subunit vaccine, called HZ/su vaccine, demonstrated significant risk reduction of herpes zoster in adults aged ! 50 years. 17 Given the concerns about the theoretical risk that the attenuated live vaccines may cause serious disease in immunocompromised hosts, this HZ/su vaccine has the potential to benefit HIV-positive patients. 18 In Taiwan, Hung et al 7 reported that the incidence of herpes zoster in HIV-positive patients had declined from 17.21/100 person-years in the pre-cART era (prior to 1997) to 5.05/100 person-years in the post-cART era (between 1997 and 2003) (p < 0.0001), and baseline CD4 count was a significant risk factor associated with herpes zoster. To obtain current epidemiological data for better vaccination policies, this study aimed to assess the incidence and identify risk factors of herpes zoster in HIV-positive patients initiating cART in Taiwan.
Materials and methods

Patients and setting
Between June 1, 2012 and May 31, 2015, we conducted a prospective cohort study to identify cases of herpes zoster in cART-naïve HIV-positive adult patients who initiated cART at the National Taiwan University Hospital, Taipei, Taiwan. Patients were followed from the initiation of cART until the date of first episode of herpes zoster, loss to follow up, death, or end of observation (December 31, 2015). Herpes zoster was diagnosed based on the characteristic skin findings, whereas previous herpes zoster was defined as having an episode of herpes zoster prior to the initiation of cART.
In Taiwan, cART has been provided free of charge since its introduction in April 1997, and HIV-positive Taiwanese patients receive HIV care according to the national treatment guidelines at designated hospitals around Taiwan. Plasma HIV-1 RNA load (PVL) and CD4 count were determined at baseline, 4 weeks after initiation of cART, and every 12 weeks thereafter within the 1 st year of cART and every 24 weeks subsequently in patients who are on stable cART with good viral suppression. All of the patients were enrolled in the case management program implemented by the Taiwan Centers for Disease Control to provide support, counseling, and linkage to and retention in HIV care fort the HIV-positive patients.
During the study period, cART was defined as combinations of two nucleos(t)ide reverse-transcriptase inhibitors with one non-nucleoside reverse-transcriptase inhibitor, boosted protease inhibitor or unboosted atazanavir, or integrase inhibitor. PVL and CD4 count quantified with the use of the Cobas Amplicor HIV-1 Monitor Test, version 1.5, (Roche Diagnostics Corporation, Indianapolis, IN, USA) and FACSFlow (Becton Dickinson, CA), respectively.
Study design and data collection
We used a standardized case record form to collect information on the demographic and clinical characteristics of the patients, including age, sex, risk behaviors of HIV-1 transmission, prior episode of herpes zoster, duration from cART initiation to the development of herpes zoster, as well as PVL and CD4 count at baseline and during follow up. To better delineate the risk factor for development of herpes zoster, a caseecontrol study was conducted with two control patients without herpes zoster who were matched for one case patient with herpes zoster with regard to age (AE3 years), sex, risk behaviors, and date of cART initiation (AE2 weeks). Only the first episode of herpes zoster was included for analysis. The patients were censored when herpes zoster occurred after initiation of cART, when the patients were lost to follow up, or when the observation ended (December 31, 2015), whichever occurred first.
The study was approved by the Research Ethics Committee of the hospital (Registration Number, 201003112R), and the requirement for written informed consent from participants prior to participation in the study was waived.
Statistical analysis
Statistical analyses were performed using SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were reported as mean AE standard deviation (SD), and compared using Student t test. Categorical variables were expressed as percentage of the total number of patients analyzed, and compared using chi-square test. To identify the factors associated with development of herpes zoster, the variables with p values < 0.05 in univariate analysis were entered into the multivariate logistic regression analysis. The KaplaneMeier method was used to assess time to cumulative probabilities of herpes zoster free condition by different categories of baseline CD4 count (<200 cells/mL, 200e349 cells/mL, 350e499 cells/mL, and !500 cells/mL, respectively), which were compared using log-rank test. A p value < 0.05 was considered statistically significant. Data are presented as mean AE SD or n (%). ART Z antiretroviral therapy; AZT Z zidovudine; HIV Z human immunodeficiency virus; IDU Z injected drug user; NA Z not available; PVL Z plasma HIV-1 RNA load; SD Z standard deviation.
Results
During the 3-year study period, a total of 826 patients initiated cART at National Taiwan University Hospital. The patients had a mean age of 32.9 years; 97.0% were men; 93.1% were men who have sex with men; and 7.7% had prior herpes zoster. The mean baseline CD4 count and PVL were 286 cells/mL and 4.90 log 10 copies/mL, respectively. Almost one-third of the patients (32.4%) had a baseline CD4 count < 200 cells/mL (Table 1) . cART containing zidovudine/ lamivudine was initiated in 43.3% (358/826) of the patients; however, 69.3% of those 358 patients initiating zidovudinecontaining regimens had to switch from zidovudine/lamivudine to other nucleoside reverse transcriptase inhibitors. After a mean observation duration of 634 days (SD, 348), herpes zoster developed in 54 patients (6.5%) after cART initiation, and nine (18.8%) of them had had herpes zoster prior to cART initiation. This corresponded to an overall incidence rate of 3.61/100 person-years. The mean interval from cART initiation to onset of herpes zoster was 227 days (SD, 265). Most of the episodes (79.6%) occurred within 1 year of cART initiation.
Demographic data and clinical characteristics between patients with and without development of herpes zoster after initiation of cART are shown in Table 1 . Compared with patients without herpes zoster after cART, those with herpes zoster were older (mean age, 36.3 years vs.
32.7 years, p Z 0.005) and more likely to have had prior herpes zoster (18.8% vs. 6.9%, p Z 0.007), and had a lower mean baseline CD4 count (208 cells/mL vs. 292 cells/mL, p Z 0.001) and a higher mean baseline PVL (5.22 log 10 copies/mL vs. 4.87 log 10 copies/mL, p Z 0.001).
One month after initiation of cART, patients with herpes zoster continued to have a lower mean CD4 count (344 cells/mL vs. 405 cells/mL, p Z 0.043) and a higher mean PVL (2.93 log 10 copies/mL vs. 2.58 log 10 copies/mL, p Z 0.002). Four months after initiation of cART, patients with herpes zoster tended to have a lower mean CD4 count (403 cells/mL vs. 457 cells/mL, p Z 0.091) but had a higher mean PVL (2.15 log 10 copies/mL vs. 1.74 log 10 copies/mL, p Z 0.010).
KaplaneMeier plots for cumulative probability of herpes zoster in patients with different categories of baseline CD4 counts during observation are shown in Figure 1 . Patients with lower baseline CD4 counts were more likely to develop zoster (log-rank test p Z 0.012; Figure 1) . In multivariate analysis, prior herpes zoster [adjusted odds ratio (AOR) Z 3.143; 95% confidence interval (CI), 1.385e7.133; p Z 0.006] and baseline CD4 count < 200 cells/mL (AOR 2.034, 95% CI 1.020e4.057, p Z 0.044) were independent risk factors for herpes zoster in HIV-positive patients initiating cART (Table 2 ).
In the caseecontrol study, the clinical characteristics of the matched pairs (1:2) of patients with and without development of herpes zoster after initiation of cART are shown in Table 3 . Six case patients did not have suitable controls, and only one matched control was identified for each of 10 patients. Compared with control patients, case patients were more likely to have prior herpes zoster (18.8% vs. 3.8%, p Z 0.012), and had a lower mean baseline CD4 count (208 cells/mL vs. 284 cells/mL, p Z 0.015) and a higher mean baseline PVL (5.22 log 10 copies/mL vs. 4.80 log 10 copies/mL, p < 0.001). One month and 4 months after initiation of cART, case patients had a higher mean PVL [2.93 log 10 copies/mL vs. 2.51 log 10 copies/mL (p Z 0.004) and 2.15 log 10 copies/mL vs. 1.71 log 10 copies/mL (p Z 0.014), respectively]. Associated factors with development of herpes zoster in multivariate analysis included prior herpes zoster (AOR Z 4.735; 95% CI, 1.122e19.990; p Z 0.034) and baseline PVL > 5 log 10 copies/mL (AOR Z 2.963; 95% CI, 1.001e8.774; p Z 0.050) ( Table 4) .
Discussion
In this cohort of ART-naive HIV-positive patients, 6.5% experienced herpes zoster after cART initiation. Other studies of similar populations (homosexual males aged approx.30e40 years) in the cART era reported a relatively higher prevalence of herpes zoster, ranging from 7.9% to 14.1%. 8, 9, 19 The discrepancy may be attributable to the different ethnicities and baseline CD4 counts of the patient populations. 8 Compared with a previous observational study in Taiwan, 7 this study showed lower incidence (6.5% vs. 10.7%, p Z 0.006) with a significantly lower incidence rate than that in the pre-cART era (3.61/100 person-years vs. 17.2/100 person-years, p Z 0.004) but a similar incidence rate when compared with that in the post-cART era (3.61/100 person-years vs. 5.05/100 person-years, p Z 0.754). The decline in the incidence of herpes zoster was also demonstrated in other recent studies, 8, 10, 19 which could reflect the benefit of restoration of immunodeficiency and viral suppression by cART.
Our study found that baseline CD4 count < 200 cells/mL and prior herpes zoster were independent risk factors for the development of herpes zoster in patients initiating cART. Several recent studies also demonstrated a clear association between the CD4 counts and the risk of herpes zoster. 9, 10, 19, 20 In the French study using insurance databases, Grabar et al 19 found an inverse doseeresponse relationship between the CD4/CD8 ratio < 0.9 and the risk of herpes zoster, independent of the CD4 count and PVL, in multivariate analysis. An association between CD8 count and the risk of herpes zoster has also been described by other studies. 21, 22 In the caseecontrol study, we found that prior herpes zoster and baseline PLV > 5 log 10 copies/mL were risk factors associated with development of herpes zoster, which was different from those (prior herpes zoster and baseline CD4 count < 200 cells/mL) identified in the overall study population. Blank et al 10 found that starting cART within 90 days of the zoster episode, having a PVL > 400 copies/mL, and a CD4 < 350 cells/mL were associated with increased risk of herpes zoster. These findings suggested that markers of poor immune function, such as high PVL and low CD4 count, were predisposing factors to the development of herpes zoster, and early initiation of appropriate regimens of cART may reduce the burden of herpes zoster in HIV-positive patients.
Because of higher incidence and complications of herpes zoster in HIV-positive patients, vaccination could provide potential benefits. LAHZV is recommended to HIV-positive adults with a CD4 count >200 cells/mL. 15, 16 Despite concerns of causing disease in immunocompromised hosts, including HIV-positive populations, by LAHZV, 23, 24 a recent study by Shafran 15 recommended the administration of LAHZV to HIVpositive adults with a CD4 count >200 cells/mL, which was safe and immunogenic with no cases of vaccine strain infection. However, the lower CD4 counts, the higher the probability of herpes zoster in HIV-positive patients. For HIVpositive patients with CD4 counts < 200 cells/mL, a recombinant subunit vaccine might be an appropriate choice to prevent herpes zoster. 25 A recent phase 1/2a clinical trial by Berkowitz et al 18 noted that an adjuvanted herpes zoster subunit candidate vaccine was immunogenic in both humoral and cellular immunity and had a clinically acceptible safety profile in HIV-positive adults, including patients with cART and CD4 count < 200 cells/mL.
This study should be viewed with necessary caution in light of several limitations. First, self-reported prior herpes zoster was not documented by a health professional, but high validity to self-reports of herpes zoster suggested that herpes zoster misclassification was likely to be very low. 26 Second, as patients might present with herpes zoster in a local primary care facility, the incidence of herpes zoster experienced by patients in this cohort was likely to be underestimated. Third, information on complications of herpes zoster were unavailable, such as postherpetic neuralgia, disseminated herpes zoster, bacterial superinfection, ocular involvement, and meningoencephalitis. This precludes us from evaluating the impact of herpes zoster on HIV-positive patients. Fourth, our results were derived from patients followed at a single, urban institution with a high proportion of men who have sex with men, and the results may not be generalized to other clinical settings. Data are presented as mean AE SD or n (%). ART Z antiretroviral therapy; AZT Z zidovudine; HIV Z human immunodeficiency virus; IDU Z injection drug user; PVL Z plasma HIV-1 RNA load; SD Z standard deviation.
In conclusion, 6.5% of HIV-positive Taiwanese patients developed herpes zoster after initiation of cART, with an overall incidence rate of 3.61/100 patient-years. The associated factors of zoster development included prior herpes zoster and baseline CD4 count < 200 cells/mL or baseline PVL > 5 log 10 copies/mL.
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